Erin VanDyke: Shifting Attention Upstream in VTE Care Through NBCA Centers of Excellence
Erin VanDyke, Vice President of National Blood Clot Alliance Centers of Excellence, shared a post on LinkedIn:
“Pulmonary embolism (PE) often takes the spotlight in venous thromboembolism (VTE) discussions, and understandably so—it is frequently life-threatening. But the most common precursor to PE is deep vein thrombosis (DVT), and this is where we have a real opportunity to intervene earlier.
- Up to 50% of patients with PE also have concomitant DVT
- An estimated 900,000 Americans are affected by VTE each year, with 100,000+ deaths annually—many preventable
Despite these numbers, resources and infrastructure to support DVT identification, follow-up, and longitudinal care remain limited compared to PE. Clinical pathways vary widely, and standardized approaches are often lacking.
National Blood Clot Alliance is leading national efforts across the full VTE disease state—PE and DVT alike. Through initiatives like the NBCA Centers of Excellence program, we are partnering with hospitals and clinical teams to:
- Standardize care protocols
- Strengthen follow-up pathways
- Provide education and resources that support providers and patients across the spectrum of VTE
We encourage centers to explore the NBCA COE program and stay tuned for new initiatives launching to support community DVT centers.
Our collective challenge—and opportunity—is to shift attention upstream. By addressing DVT earlier and more consistently, we can reduce downstream PE and ultimately save lives.”
More information here.
Keep up with Hemostasis Today.
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies